Immunovant CLO granted RSUs and stock options
Immunovant, Inc. granted Chief Legal Officer Christopher Van Tuyl equity awards on April 7, 2026.
Rhea-AI Filing Summary
Immunovant, Inc. granted Chief Legal Officer Christopher Van Tuyl equity awards on April 7, 2026. He received stock options for 59,820 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036.
He was also granted 41,343 restricted stock units (RSUs), each representing one share of common stock. Both the RSUs and the option shares vest as to 25% on April 1, 2027, with the remaining amounts vesting in regular installments thereafter, contingent on his continued service. Following the grant, he directly holds 188,396 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 101,163 shares
Grant/Award
2 txns
Insider
Van Tuyl Christopher
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 59,820 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 41,343 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 59,820 contracts (Direct);
Common Stock — 188,396 shares (Direct)
Footnotes (2)
- F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
- F2. These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
Stock options granted: 59,820 shares
Option exercise price: $24.61 per share
Option expiration date: April 7, 2036
+3 more
6 metrics
Stock options granted
59,820 shares
Stock Option grant on April 7, 2026
Option exercise price
<money>$24.61</money> per share
Exercise price for 59,820 options
Option expiration date
April 7, 2036
Term of newly granted options
RSUs granted
41,343 units
Restricted stock units granted April 7, 2026
Initial vesting date
April 1, 2027
25% of RSUs and options vest
Common shares held after grant
188,396 shares
Direct common stock ownership after RSU grant
Key Terms
restricted stock units ("RSUs"), 2019 Equity Incentive Plan, contingent right, vest, +1 more
5 terms
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan")."
contingent right financial
"Each RSU represents a contingent right to receive one share of common stock"
vest financial
"The RSUs will vest as to 25% of the total shares on April 1, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
stock options financial
"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25%"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Immunovant (IMVT) grant to its Chief Legal Officer?
Immunovant granted its Chief Legal Officer stock options for 59,820 shares and 41,343 restricted stock units. The awards come under the 2019 Equity Incentive Plan and represent compensation, rather than open‑market purchases, tied to his ongoing service.
How do Christopher Van Tuyl’s new RSUs at Immunovant (IMVT) vest?
The 41,343 RSUs vest 25% on April 1, 2027, with the remaining 75% vesting in twelve substantially equal quarterly installments. Vesting is conditioned on Christopher Van Tuyl’s continuous service with Immunovant throughout the vesting period.
What is the exercise price and term of the new Immunovant (IMVT) stock options?
The newly granted stock options have an exercise price of $24.61 per share and expire on April 7, 2036. They cover 59,820 shares of common stock and vest over time, beginning April 1, 2027, subject to continued service.
When do the new stock options for Immunovant (IMVT) CLO begin vesting?
Both the stock options and RSUs begin vesting on April 1, 2027, when 25% of each award vests. The remaining option shares vest in thirty‑six monthly installments thereafter, assuming the Chief Legal Officer remains in continuous service.
Under which plan were Immunovant (IMVT) RSUs and options granted to the CLO?
Both the restricted stock units and stock options were granted under Immunovant’s 2019 Equity Incentive Plan. The plan governs equity‑based compensation awards, including vesting schedules and conditions tied to the executive’s continued service with the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
